October 7, 2014 | The Israeli pharmaceutical company developed an ADHD treatment drug, Alcobra Pharma announced positive results in a Phase III clinical trial on the drug. The drug, Metadoxine Extended Release (MDX), will be used in adults to treat ADHD. However, the market did not respond positively to the news, with the company’s share price dropping 45.36 percent in premarket trading to $7.71 at a market cap of $192.77 million. According to the company, MDX showed statistically significant improvement in ADHD symptoms compared to a placebo when measured on the Conner’s Adult ADHD Rating Scale. The trial was conducted on 300 patients at 18 sites in the United States and 2 in Israel. Alcobra Pharma is headed by CEO Yaron Daniely.